metronomic effect as a new hypothesis in maintenance therapy of acute lymphoblastic leukemia

Authors

babak abdolkarimi assistant professor of pediatric department, lorestan university of medical science, khoramabad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی لرستان (lorestan university of medical sciences)

abstract

0

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Metronomic Maintenance Therapy in Refractory Acute Myeloblastic Leukemia with Monosomy 7

Patients with acute myeloblastic leukemia (AML) with monosomy 7 are a group of patients with refractory AML who have a very poor prognosis. Therefore, rationally designed new therapies, including metronomic chemotherapy regimen with histidine deacetylase inhibitors (Valporic acid, ATRA) are being investigated as potential treatments for the population of refractory cases of AML. Herein, we repo...

full text

UBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia

Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1...

full text

metronomic maintenance therapy in refractory acute myeloblastic leukemia with monosomy 7

patients with acute myeloblastic leukemia (aml) with monosomy 7 are a group of patients with refractory aml who have a very poor prognosis. therefore, rationally designed new therapies, including metronomic chemotherapy regimen with histidine deacetylase inhibitors (valporic acid, atra) are being investigated as potential treatments for the population of refractory cases of aml. herein, we repo...

full text

Rituximab as therapy for acute lymphoblastic leukemia.

DT Frontline treatment approaches for newly diagnosed ALL have evolved from “one size fits all” chemotherapy regimens to subtype-oriented chemotherapy programs. The traditional risk factors that influence selection of therapy primarily include characteristics of the host, such as age, and features of the disease, such as lineage (T-lymphoblastic, B-lymphoblastic, or Burkitt-type [mature B-cell]...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of blood and cancer

جلد ۸، شماره ۳، صفحات ۸۸-۸۹

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023